Trial · NCT00735371
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks | Lisdexamfetamine Dimesylate (LDX) 30 mg | -18.3 | Standard Error 1.25 | Units on a scale | |
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks | LDX 50 mg | -21.1 | Standard Error 1.28 | Units on a scale | |
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks | LDX 70 mg | -20.7 | Standard Error 1.25 | Units on a scale | |
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks | Placebo | -12.8 | Standard Error 1.25 | Units on a scale | |
| Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | Lisdexamfetamine Dimesylate (LDX) 30 mg | 44 | Participants | ||
| Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | LDX 50 mg | 53 | Participants | ||
| Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | LDX 70 mg | 57 | Participants | ||
| Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | Placebo | 30 | Participants | ||
| Youth Quality of Life-Research Version (YQOL-R) Total Score | Lisdexamfetamine Dimesylate (LDX) 30 mg | Baseline | 79.3 | Standard Deviation 10.03 | Units on a scale |
| Youth Quality of Life-Research Version (YQOL-R) Total Score | LDX 50 mg | Baseline | 80.5 | Standard Deviation 10.63 | Units on a scale |
| Youth Quality of Life-Research Version (YQOL-R) Total Score | LDX 70 mg | Baseline | 78.8 | Standard Deviation 15.38 | Units on a scale |
| Youth Quality of Life-Research Version (YQOL-R) Total Score | Placebo | Baseline | 79.2 | Standard Deviation 11.08 | Units on a scale |
| Youth Quality of Life-Research Version (YQOL-R) Total Score | Lisdexamfetamine Dimesylate (LDX) 30 mg | 4 Weeks | 81.1 | Standard Deviation 11.09 | Units on a scale |
| Youth Quality of Life-Research Version (YQOL-R) Total Score | LDX 50 mg | 4 Weeks | 81.3 | Standard Deviation 11.86 | Units on a scale |
| Youth Quality of Life-Research Version (YQOL-R) Total Score | LDX 70 mg | 4 Weeks | 81.3 | Standard Deviation 14.66 | Units on a scale |
| Youth Quality of Life-Research Version (YQOL-R) Total Score | Placebo | 4 Weeks | 81.3 | Standard Deviation 12.16 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00735371/results